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Abstract
Background: HIV-1 subtype C infections account for over half of global HIV infections, yet the vast focus of HIV-1
research has been on subtype B viruses which represent less than 12% of the global pandemic. Since HIV-1 reverse
transcriptase (RT) is a major target of antiviral therapy, and since differential drug resistance pathways have been
observed among different HIV subtypes, it is important to study and compare the enzymatic activities of HIV-1 RT
derived from each of subtypes B and C as well as to determine the susceptibilities of these enzymes to various RT
inhibitors in biochemical assays.
Methods: Recombinant subtype B and C HIV-1 RTs in heterodimeric form were purified from Escherichia coli and
enzyme activities were compared in cell-free assays. The efficiency of (-) ssDNA synthesis was measured using gel-
based assays with HIV-1 PBS RNA template and tRNA3
Lys as primer. Processivity was assayed under single-cycle
conditions using both homopolymeric and heteropolymeric RNA templates. Intrinsic RNase H activity was
compared using 5’-end labeled RNA template annealed to 3’-end recessed DNA primer in a time course study in
the presence and absence of a heparin trap. A mis-incorporation assay was used to assess the fidelity of the two
RT enzymes. Drug susceptibility assays were performed both in cell-free assays using recombinant enzymes and in
cell culture phenotyping assays.
Results: The comparative biochemical analyses of recombinant subtype B and subtype C HIV-1 reverse
transcriptase indicate that the two enzymes are very similar biochemically in efficiency of tRNA-primed (-) ssDNA
synthesis, processivity, fidelity and RNase H activity, and that both enzymes show similar susceptibilities to
commonly used NRTIs and NNRTIs. Cell culture phenotyping assays confirmed these results.
Conclusions: Overall enzyme activity and drug susceptibility of HIV-1 subtype C RT are comparable to those of
subtype B RT. The use of RT inhibitors (RTIs) against these two HIV-1 enzymes should have comparable effects.
Introduction
Human immunodeficiency virus type 1 (HIV-1) genetic
diversity is reflected by the existence of three groups
( M ,N ,a n dO ) ,o fw h i c hg r o u pMi sr e s p o n s i b l ef o r
greater than 90% of HIV-1 infections. Currently, there
are at least nine group M subtypes (A, B, C, D, F, G, H,
J, and K) and numerous recombinant forms that show
25-35% overall genetic variation that includes 10-15%
variability in reverse transcriptase (RT) [1,2]. Subtype C
variants of HIV-1 are responsible for over 50% of the
worldwide pandemic, and largely represent the domi-
nant viral species in Sub-Saharan Africa and India [3].
Despite this, no work has yet been reported on the com-
parative biochemistry of RT enzymes derived from
either subtype B or C. Most data have been inferred
from enzymatic studies on prototypic subtype B viruses
[4].
HIV-1 RT is a multi-functional enzyme that possesses
both RNA- and DNA-directed DNA polymerase activ-
ities as well as an RNase H activity [5]. Due to its key
role in HIV-1 replication, RT has been a major target
for development of antiviral drugs. RT inhibitors (RTIs)
are core constituents of antiretroviral (ARV) regimens
and include both nucleoside and nucleotide RTIs
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Currently, eight NRTIs and four non-nucleoside reverse
transcriptase inhibitor (NNRTIs) are approved for treat-
ment of HIV-1 infection. The former are activated by
host enzymes to their active triphosphate forms (dipho-
sphate for tenofovir), which bind to the active site of
RT, acting as competitive inhibitors of RT and interfer-
ing with the addition of incoming nucleosides to grow-
ing viral DNA chains. The NNRTIs are non-competitive
inhibitors that bind allosterically to an asymmetric and
hydrophobic cavity, about 10 Å away from the catalytic
site of the HIV-1 RT [7]. RNase H is responsible for
degradation of the RNA template after the synthesis of
minus-strand strong stop (-ss) DNA [8] and is also a
potential target for drug discovery [9]. Despite remark-
able progress in the development of antivirals, the
occurrence of drug resistance remains a problem in the
management of HIV infection.
RT exists as a heterodimer that consists of 66 kDa
(p66) and 51 kDa (p51) subunits. The p51 subunit
shares the same N-terminal sequence, as does p66, but
lacks the C-terminal 140 amino acids of the latter.
Although p51 provides RT with essential structural and
conformational stability, p66 is the catalytically active
subunit and includes the N-terminal polymerase domain
(residues 1-321) and C-terminal RNase H domain (resi-
dues 441-560), linked by a connection domain (cn) (resi-
dues 322-440) [7]. All of these domains can be involved
in drug resistance [10]. Enzymatic studies using purified
subtype B recombinant RT have provided valuable infor-
mation on catalytic properties and mechanisms of resis-
tance [11].
Differences among subtypes can occur in the develop-
ment of and interactions amo n gd r u gr e s i s t a n c em u t a -
tions. This genetic diversity has the potential to
influence rates of development of drug resistance and
relevant mutational pathways [12-15]. Although antire-
troviral drugs have been designed based on subtype B
RT, this is the first report of a comparative biochemical
analysis of the subtype B and C RT enzymes.
Results
Purification of recombinant HIV-1 RTs from subtype B
and subtype C
The subtype C HIV-1 RT sequence used in this study
differs from consensus subtype B RT by 6.96% of amino
acids. Thirty-nine amino acids were variable in subtype
C RT, of which 16 were in the DNA polymerase domain
(residues 1-321), 12 were in the connection domain
(residues 322-440) and 11 were in the RNase H domain
(residues 441-560). This level of variation is in agree-
ment with previous reports showing that HIV-1 RT sub-
t y p e sd i f f e rf r o mo n ea n o t h e rb y≈ 5%-6% of amino
acids [16]. By co-expression of the HIV-1 protease (PR)
with the RT coding sequence in one plasmid and
through use of the well-established method of immobi-
lized metal affinity chromatography (IMAC), followed
by ion-exchange chromatography [17], recombinant het-
erodimeric (p66/p51) RTs of both subtypes B and C
were purified to >95% homogeneity and shown to pos-
sess similar molar ratios (Figure 1.). This indicates that
the amino acid polymorphisms in subtype C RT do not
affect protease cleavage, p66/p51 heterodimer formation,
or RT purification [18]. Through individual expression
of the p66 and p51 subunits from separate plasmids and
mixing the E. coli cell paste containing both subunits
prior to cell lysis, various labs have obtained homoge-
nous HIV-1 RT heterodimers [19-21]. This strategy has
also been used for purification of heterodimeric HIV-1
RTs from different subtypes [22]. The results presented
here show that the one plasmid co-expression strategy is
effective, non-laborious, and convenient, especially for
the simultaneous biochemical analysis of a large panel
of RTs of different subtypes. The inclusion of a 6-His
tag in recombinant RT enzymes has been shown to be
devoid of deleterious effects on polymerase, RNase H,
tRNA binding, and RT inhibitor susceptibilities [23-25].
To determine the specific activity of the recombinant
enzyme preparations, DNA polymerase activity was mea-
sured using synthetic poly(rA)/oligo(dT)12-18 template/
Figure 1 Purified recombinant heterodimer RT enzymes of
subtypes B and C were analyzed by 8% SDS-PAGE after
Coomassie-Brilliant Blue staining. M (molecular weight markers in
kilodaltons are shown on the left); B RT/C RT, (subtype B/C HIV-1
wild-type RTs). The positions of purified recombinant RT
heterodimer subunits of both subtypes that possessed a similar ratio
of p51/p66 are indicated on the right.
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time-course reaction. The calculated initial velocities
were then divided by the concentration of enzyme used
in the assay to determine the specific activity of the
recombinant RT preparations. Recombinant RTs from
HIV-1 subtype B and subtype C shared similar activities
at 238 units/μg and 233 units/μg respectively. This result
also confirmed the efficiency of the expression and purifi-
cation procedure.
Susceptibilities of HIV-1 subtype B and subtype C
recombinant RTs and viruses to RT inhibitors
To test whether NRTIs and NNRTIs have similar inhibi-
tory effects on HIV-1 subtype B and C RT, recombinant
RT heterodimers were analyzed in cell-free RNA-depen-
dent DNA polymerase assays in the presence of NRTIs
ZDV-TP, 3TC-TP, and TFV-DP, or NNRTIs NVP, EFV,
and ETR. The results of Table 1 show that both the
subtype B and the two subtype C RT enzymes from iso-
lates BG05 and M01 (GenBank accession number
AF492609 and AF492603) were inhibited to similar
extent by all of the RT inhibitors tested. The reason for
using two RTs of subtype C was to reduce the possibi-
lity of natural variability. We also performed phenotypic
assays in cord blood mononuclear cells using wild-type
viruses from both subtypes and found that they shared
similar susceptibilities to all of the RT inhibitors tested
i.e. ZDV, 3TC,TFV, NVP, EFV and ETR (Table 2), in
agreement with previous data [26].
Efficiency of (-) ssDNA synthesis from the natural tRNA3
Lys
primer
The first step in reverse transcription requires human
tRNA3
Lys as primer, which is annealed to a region near
the 5’-end of viral RNA termed the primer binding site
(PBS). The efficiency of tRNA-primed synthesis of
minus-strand strong stop (-) ssDNA correlates with viral
replication competence, and this step can sometimes be
impeded by the presence of drug resistance mutations
[27,28]. We therefore investigated whether the two RT
enzymes exhibited differences in the efficiency of (-)
ssDNA synthesis by using a HIV-1 PBS RNA template
and 5’-end
32P labeled tRNA3
Lys primer. Full-length
DNA products were monitored in time course reactions.
Figure 2 shows that both enzymes displayed similar
levels of tRNA-primed synthesis of (-) ssDNA. This
result also indicates that the two enzymes exhibited
similar efficiency in regard to tRNA-primed (-) ssDNA
synthesis.
Processivity analysis of recombinant HIV-1 subtype B and
subtype C RTs
The processivity of a polymerase is defined as the
number of nucleotides incorporated in a single round
of binding, elongation, and dissociation. Earlier studies
showed that HIV replication efficiency is related in
part to RT processivity [29,30]. We compared the
enzyme processivity of the two subtype RT enzymes by
using homopolymeric poly (rA) RNA template (average
length 500 nt) annealed to 5’
32P-labeled oligo dT pri-
mers in a fixed-time experiment in the presence of
h e p a r i nt r a pt oe n s u r et h a te a c hs y n t h e s i z e dD N A
molecule resulted from a single processive cycle. Figure
3 shows that both enzymes share similar processivity
on the homopolymeric RNA template within a size
range of the longest products at 160 nt-260 nt. We
also compared the processivity of the two RT enzymes
using a heteropolymeric RNA template under three dif-
ferent concentrations of dNTPs. The results of Figure 4
clearly demonstrate that both enzymes possessed simi-
lar processivity at all three dNTP concentrations
dNTPs tested. Primary subtype C HIV-1 isolates have
been reported to be less fit than subtype B isolates in
PBMCs, CD4+ T cells, and macrophages [31], and
these differences seem to be related to lesser efficiency
at host cell entry [32]. The results presented here show
that subtype C RT does not have a processivity defect
compared to subtype B RT.
Table 1 RT inhibitor susceptibilities for HIV-1 subtype B
and subtype C recombinant RTs
RT inhibitors IC50 (μM)
a
B RT-1
b B RT-2
c C RT-1
d C RT-2
e
ZDV-TP 3.1 ± 0.5 2.9 ± 0.4 4.3 ± 0.4 3.8 ± 0.5
3TC-TP 2.7 ± 0.3 4.2 ± 0.5 3.7 ± 0.6 4.1 ± 0.4
TFV-DP 2.5 ± 0.3 2.1 ± 0.3 2.6 ± 0.5 2.9 ± 0.4
NVP 3.2 ± 0.4 5.3 ± 1.4 3.3 ± 0.4 4.3 ± 0.3
EFV 0.11 ± 0.03 0.22 ± 0.03 0.20 ± 0.02 0.18 ± 0.02
ETR 0.17 ± 0.03 0.16 ± 0.02 0.15 ± 0.04 0.19 ± 0.03
a Data represent means ± standard deviations of three determinations.
b NL4-3
c HXB2
d Isolate BG05 (GenBank accession number AF492609)
e Isolate M01 (GenBank accession number AF492603)
Table 2 RT inhibitor susceptibilities for HIV-1 subtype B
and subtype C viruses
RT inhibitors EC50 (nM)
a
Subtype B HIV-1 Subtype C HIV-1
ZDV 12.9 ± 5.9 34.8 ± 12.9
3TC 45.4 ± 16.4 105.9 ± 40.2
TFV 334.8 ± 140.9 304.8 ± 93.1
NVP 50.2 ± 29.6 170.4 ± 79.5
EFV 0.6 ± 0.2 1.3 ± 0.4
ETR 0.9 ± 0.4 0.5 ± 0.01
a Data represent means ± standard deviations of three determinations.
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subtype C RTs
HIV-1 RT has low fidelity compared with RTs of other
retroviruses and cellular DNA polymerases. Point muta-
tions in HIV-1 RT may strongly affect the fidelity of
HIV-1 RT, and we and others have shown that the fide-
lity of DNA polymerization of M184V-mutated HIV-1
RT is significantly higher than that of wild-type RT [33].
In order to assess the fidelity of recombinant subtype B
and C RTs, we performed misincorporation experiments
to monitor primer extension in the absence of a single
dNTP complementary to various template nucleotides.
Figure 2 Efficiency of tRNA3
Lys -primed (-) ssDNA synthesis in
cell-free assays. The efficiencies of synthesis of (-) ssDNA with HIV-
1 subtype B and subtype C wild-type RTs were compared in time
course experiments using 5’-end
32P-labeled human natural tRNA3
Lys
as primer and HIV-1 PBS RNA as template. The HIV-1 PBS RNA
template used in this system consists of 258 nucleotides (nt) at the
5’ end of the HIV-1 genome, which contains the R, U5, and PBS
regions. Synthesis of full-length DNA (FL DNA) by recombinant RT
enzymes was monitored in time-course experiments. Reactions were
initiated by the addition of MgCl2 and dNTPs and stopped at
different time points during a period of 45 min. The position of the
full-length DNA product (FL DNA) is shown on the right.
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Figure 3 Processivity assay using a homopolymeric RNA
template. Processivity of the recombinant HIV-1 subtype B and C
RT enzymes was assessed using homopolymeric RNA template poly
(rA) and oligo (dT)12-18 DNA primer. The DNA primer was labeled
with
32P at the 5’-terminus and annealed to poly (rA) RNA template
at an equimolar ratio. Processivities were analyzed by monitoring
the size distribution of DNA products in fixed-time experiments in
the presence of heparin trap. Parallel reactions were run in the
absence of trap to ensure that similar amounts of enzyme activities
were present in the reactions. The sizes of some fragments of the
standard are indicated on the left side of the panel. All reaction
products were resolved by denaturing 6% polyacrylamide gel
electrophoresis and visualized by phosphorimaging. M: molecular
size standards. C: control reaction in which the heparin trap was
preincubated with substrates before the addition of RT.
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protocol that qualitatively monitors both misinsertion
and mismatch extension in the presence of biased dNTP
pools containing only three of the four natural dNTPs.
Under these conditions, the elongation of the primer
p a s tat e m p l a t en u c l e o t i d ec o m p l e m e n t a r yt ot h e
excluded dNTP requires the insertion of an incorrect
nucleotide (misincorporation) and further extension of
the generated mismatch primer (mispair extension). In
the absence of one of the dNTPs, primer extension stalls
o n eb a s eb e f o r et h et e m p l a t en u c l e o t i d ef o rw h i c ht h e
complementary dNTP is withheld (stop site). A higher
efficiency of primer extension beyond the stop site
reflects a higher ability to utilize incorrect dNTPs, i.e.
lower fidelity of the RT. When incubated with mixtures
of only three dNTPs in the presence of template-primer
ppt57D/ppt17D, both subtype C and B RTs catalyzed
substantial extension past the stop sites on the template,
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Figure 4 Processivity assay using a heteropolymeric HIV PBS RNA template. Processivity of the recombinant HIV-1 subtype B and C RT
enzymes was assessed using heteropolymeric HIV PBS RNA template and D25 DNA primer. The DNA primer D25 was labeled with
32P at the 5’-
terminus and annealed to the RNA template at an equimolar ratio. Processivities were analyzed by monitoring the size distribution of DNA
products in fixed-time experiments at three different concentrations of dNTPs in the presence of heparin trap (+ Trap). Parallel reactions were
run in the absence of trap (- Trap) at 200 μM of dNTPs to ensure that similar amounts of enzyme activities were present in the reactions. The
sizes of some fragments of the
32P-labeled 25bp DNA ladder (Invitrogen) in nucleotide (nt) bases are indicated on the left side of the panel. All
reaction products were resolved by denaturing 6% polyacrylamide gel electrophoresis and visualized by phosphorimaging. Trap control: control
reactions in which the heparin trap was preincubated with substrates before the addition of RT enzymes. T/P: control reaction in which no RT
enzymes were included. Positions of
32P -labeled D25 primer (
32P -D25) and the 471-nt full-length extension DNA (FL DNA) product are
indicated on the right.
Xu et al. Retrovirology 2010, 7:80
http://www.retrovirology.com/content/7/1/80
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tions that excluded one complementary dNTP, both
RTs catalyzed similar extensions beyond the stop. In
particular, both RTs showed the highest levels of exten-
sion in the minus-dCTP reaction, followed by those
involving minus-dATP, minus-dTTP and minus-dGTP.
These results show that subtype B and C RT possess a
similar degree of fidelity.
RNase H activity
RNase H activity is an integral part of RT function and
is essential for viral replication [34]. Mutations abrogat-
ing the degradation of template RNA can impact resis-
tance levels against certain NRTIs [35]. Therefore, we
compared the intrinsic RNase H activities of subtype B
and C RTs using a 40-mer RNA template that was
32P-
labeled at its 5’-end and annealed to an unlabeled 32-
mer DNA primer, such that there was a 8-nt overhang
at the 5’-end of the RNA. Equivalent amounts of RT
activity were added to the template primer and incu-
bated in the absence of dNTPs. Time-course experi-
ments were employed to compare RNase H cleavage
efficiencies in the context of the two RT enzymes.
Figure 6 shows that both RTs displayed similar patterns
and rates of template cleavage, indicating that they
share a common profile of RNase H activity.
Discussion
This manuscript represents the first attempt of its type to
directly compare RT enzymes of different subtypes in
regard to processivity, fidelity, RNase H activity, and sus-
ceptibility to RT inhibitors. Moreover, our analysis has
been conducted using both homopolymeric and hetero-
polymeric templates. We have further documented that
few differences exist among the various RT enzymes stu-
died in regard to each of these characteristics.
These findings are important because of the possibility
that factors that relate to polymorphisms within RT
could potentially be responsible for appearance of muta-
tions related to drug resistance and/or susceptibilities to
HIV inhibitors in a manner that would distinguish
between HIV subtypes. Were such differences to be
important in regard to enzyme processivity and/or other
characteristics of biochemical behaviour, it might follow,
in turn, that different therapeutic regimens might be
recommended for different HIV subtypes. The fact that
Figure 5 Misincorporation assay. (A) Graphic representation of the template and primer system used to monitor the misincorporation
efficiency of recombinant subtype B and C RT enzymes. The
32P-labeled 17-mer primer ppt17D annealed to 57-mer DNA template ppt57D was
extended by HIV-1 subtype B and C recombinant RTs at 37°C for 5 min. The extension reactions were performed in the presence of all four
complementary dNTPs, or, alternatively, in the absence of one of the dNTPs. The lanes marked with -A, -G, -C and -T indicate the missing
nucleotide. Lanes marked with C indicate that all four dNTPs were included in the dNTP mix. Both RTs displayed similar levels of primer
extension in the presence of all four dNTPs. P and FL indicate the positions of unextended primer and full-length extended products,
respectively.
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drugs used to treat subtype B infections should have
equal relevance to HIV infections of other subtypes. This
relieves a major concern and is of clinical significance.
On the other hand, differences in regard to viral template
sequences can directly lead to differential appearance of
resistance mutations [14,36,37]. This notwithstanding,
choices of antiretroviral therapies to be used in therapy
should not be affected. Of course, relevant considerations
in such decision-making include drug efficacy and toler-
ability as well as convenience of dosing.
The fact that different mutations may sometimes
appear differentially in regard to viruses of different sub-
types may have implications in regard to secondary
treatment strategies in the aftermath of treatment fail-
ure. This is a different topic than that of the initial use
of antiretroviral drugs discussed here, and may also have
implications for transmitted drug resistance. This rein-
forces the need to conduct genotyping prior to com-
mencement of antiretroviral therapy in newly infected
individuals and/or individuals about to undergo therapy
for the first time.
The fact that RT polymorphisms do not appear to
impact on enzyme function, as studied by multiple
methods in this manuscript, is encouraging news in
regard to future development of antiretroviral drugs.
Previous findings from our laboratory have also indi-
cated a paucity of differences among HIV integrase
enzymes of different subtypes in regard to both 3’-pro-
cessing and strand-transfer activities [38]. Future studies
should be carried out to document that polymorphisms
have little or no effect on the behaviour of HIV-1 and
other retroviral proteases, but such work has yet to be
carried out. It is important, however, to note that pre-
vious studies have suggested that resistance to HIV-1
protease inhibitors can occur along different mutational
pathways as a function of HIV-1 subtype [39]. The cur-
rent manuscript allays concerns that functional bio-
chemical differences in RT might play an important role
in regard to antiretroviral drug susceptibility.
Conclusion
Our results provide biochemical evidence that RT
enzymes from HIV-1 subtypes B and C share similar
catalytic activities in regard to each of (-) ssDNA synth-
esis, processivity of DNA polymerization, efficiency of
misincorporation, and RNase H activity. RT enzymes
and viruses from both subtypes were inhibited by
NRTIs and NNRTIs to a similar extent. These findings
are supportive of the use of recombinant RTs of either
subtype for enzyme analysis, drug design, and for study-
ing mechanisms of drug resistance.
A
Kim40R 5’-AAGCUUGGCUGCAGAAUAUUGCUAGCGGGAAUUCGGCGCG-3’
Kim32D 3’-GACGTCTTATAACGATCGCCCTTAAGCCGCGC-5’
-1 -10 -20
Kim40R 5’-AAGCUUGGCUGCAGAAUAUUGCUAGCGGGAAUUCGGCGCG-3’
Kim32D 3’-GACGTCTTATAACGATCGCCCTTAAGCCGCGC-5’
RNase H activity w/o trap RNase H activity w/ trap B
Kim32D 3 GACGTCTTATAACGATCGCCCTTAAGCCGCGC 5 Kim32D 3 GACGTCTTATAACGATCGCCCTTAAGCCGCGC 5
B RT                 C RT                          B RT                   C RT 
-18
-15
0 0 5 1 1 5 361 5 0 0 5 1 1 5361 50 5 1 1 5 3 6 1 50 511 53 61 5 (min)
-7
0 0.5 11 .5 3 6 15 0 0.5 11 .5 3 61 5    0.5 11 .5 36 15 0.5 1 1.5 3 61 5 (min)   
Figure 6 RNase H activity of HIV-1 subtype B and C recombinant wild type RTs. (A) Graphic representationo ft h es u b s t r a t eR N A / D N A
(kim40R/kim32D) duplex used to monitor the RNase H cleavage efficiency of both recombinant RTs. The 40-mer RNA kim40R was labeled at its
5’-terminus by
32P and annealed to 32-mer DNA oligo kim32D. -1, -10 and -20 are used as markers to indicate the positions of cleavage sites
relative to the 3’ end of the DNA primer. (B) The RNA-DNA substrate was incubated with the recombinant subtype B and C RT enzymes in assay
buffer as described in Materials and Methods. RNase H cleavage was initiated by the addition of MgCl2 and analyzed by monitoring substrate
cleavage in time-course experiments in the absence (left panel) or presence (right panel) of a heparin trap. The position of cleaved products is
indicated on the left. All reactions were resolved by denaturing 6% polyacrylamide gel electrophoresis.
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Chemicals, cells and nucleic acids
Poly(rA)/oligo(dT)12-18, oligo dT12-18, ultrapure dNTPs
and NTPs were purchased from GE Healthcare. [
3H]-
dTTP (70-80 Ci/mmol) and [g-
32P]-ATP were from Per-
kin Elmer Life Sciences. Natural human tRNA3
Lys puri-
fied from placenta by high-pressure liquid
chromatography (HPLC) was purchased from BIO S&T
(Montreal, Quebec, Canada). A HIV-1 PBS RNA tem-
plate spanning the 5’ UTR to the primer binding site
(PBS) was in vitro transcribed from BSSH II-linearized
p H I V - P B SD N A[ 4 0 ]b yu s i n gaT 7 - M E G A s h o r t s c r i p t
kit (Ambion, Austin, TX) as described [41].
The oligonucleotides used in this study were synthe-
sized by Integrated DNA Technologies Inc and purified
by 6% polyacrylamide-7M urea gel electrophoresis and
the sequences are as follows:
D25, 5’-GGATTAACTGCGAATCGTTCTAGCT-3’;
dPR, 5’-GTCCCTGTTCGGGCGCCA-3’;
ppt17D, 5’-TTAAAAGAAAAGGGGGG-3’;
pp57D, 5’-CGTTGGGAGTGAATTAGCCCTTCCA-
GTCCCCCCTTTTCTTTTAAAAAGTGGCTAAGA-3’;
kim40R, 5’-AAGCTTGGCTGCAGAATATTGCTAG-
CGGGAATTCGGCGCG-3’;
kim32D, 5’-CGCGCCGAATTCCCGCTAGCAATAT-
TCTGCAG-3’;
Tenofovir (TFV) and tenofovir diphosphate (TFV-DP)
were kindly provided by Gilead Sciences (Foster City,
California, USA). Zidovudine (ZDV), lamivudine (3TC),
ZDV-TP, and 3TC-TP were gifts of Glaxo-SmithKline
Inc. Etravirine (ETR) was a gift of Tibotec Inc. Efaverenz
(EFV) and nevirapine (NVP) were obtained from Bristol-
Myers Squibb Inc. and Boehringer Ingelheim Inc,
respectively.
Recombinant reverse transcriptase expression and
purification
The plasmid pRT6H-PROT [17] of which the RT coding
region is from HIV-1 HXB2 was kindly provided by
D r .S .F .J .L eG r i c e .F o rc o n s t r u c t i o no fs u b t y p eCa n d
subtype B HIV-1 using RT heterodimer expression plas-
mids pcRT6H-PROT and pbRT6H-PROT, the RT cod-
ing regions of subtype C HIV-1 isolate BG05 (GenBank
accession number AF492609) or subtype B HIV-1
pNL4-3 (GenBank accession number AF324493) were
subcloned into pRT6H-PROT by standard PCR cloning
procedure to replace the original RT coding region [41].
The accuracy of the RT coding sequence was verified by
DNA sequencing. Another subtype C RT preparation
from isolate M01 (GenBank accession number
AF492603) was prepared as reported previously [42].
Recombinant RTs were expressed and purified as
described with minor modifications [17,23]. In brief, RT
expression in E. coli M15 (pREP4) (Qiagen, Mississauga,
ON) was induced with 1 mM isopropyl-b-D-thiogalacto-
pyranoside (IPTG) at room temperature. The pelleted
bacteria were lysed under native conditions with
BugBuster Protein Extraction Reagent containing benzo-
nase (Novagen, Madison, WI) according to the manu-
facturer’s instructions. After clarification by high speed
centrifugation, the clear supernatant was subjected to
the batch method of Ni-NTA metal-affinity chromato-
graphy (QIAexpressionist) (Qiagen). All buffers con-
tained Complete protease inhibitor cocktail (Roche).
Histidine-tagged RT was eluted with an imidazole gradi-
ent. RT-containing fractions were pooled, passed
through DEAE-Sepharose (GE Healthcare), and further
purified using SP-Sepharose (GE Healthcare, Missis-
sauga, ON). Fractions containing purified RT were
pooled, dialyzed against storage buffer (50 mM Tris-HCl
(pH 7.8], 50 mM NaCl and 50% glycerol), and concen-
trated to 4 mg-8 mg/ml with Centricon Plus-20
MWCO30 kDa (Millipore). Aliquots of proteins were
stored at -80°C. Protein concentration was measured by
a Bradford protein assay kit (Bio-Rad Laboratories) and
the purity of the recombinant RT preparations was veri-
fied by SDS-PAGE.
Specific activity determination
The polymerase activity of each recombinant RT pre-
paration was evaluated in duplicate as described [42]
using varying amounts of RTs and a synthetic homopo-
l y m e r i cp o l y( r A ) / p( d T ) 12-18 template/primer (Midland
Certified Reagent Company). Each 50-μl reaction con-
tained 0.5 U/ml poly(rA)/p(dT)12-18,5 0m MT r i s - H C l
pH 7.8, 60 mM KCl, and 6 mM MgCl2. Reactions were
initiated by adding 5 μMd T T Pw i t h5μCi [
3H]-dTTP
(70-80 Ci/mmol, Perkin Elmer). Aliquots of 15 μlw e r e
r e m o v e da t3 ,7a n d1 5m i nt oe n s u r el i n e a r i t yo ft h e
reaction and quenched by the addition of ice-cold 10%
trichloroacetic acid containing 20 mM sodium pyropho-
sphate. After 30-min incubation on ice, aliquots were fil-
tered using 1.2-μm glass fiber type C filter multi-well
plates (Millipore) and washed sequentially with cold
10% trichloroacetic acid and ethanol. The extent of
radionucleotide incorporation was then determined by
liquid scintillation spectrometry. The amount of incor-
porated [
3H]-dTTP was plotted as cpm versus time and
specific activities were determined from the slopes of
the linear regression analyses. An active unit of RT was
defined as the amount of enzyme that incorporates 1
pmol of dTTP in 10 min at 37°C.
RT inhibitor susceptibility assays
Susceptibility to both NRTI and NNRTI inhibitors was
assayed using recombinant RT enzymes and heterodi-
meric HIV-1 PBS RNA template/dPR primer system as
described previously [42]. Briefly, RT reaction buffer
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mM KC1, dNTPs (5 μM each) with 2.5 μCi of [
3H]-
dTTP (70-80 mCi/mmol), 30 nM heterogeneous HIV-1
RNA template/primer, 10 units of RT, and variable
amounts of RT inhibitors was included in 50-μl reaction
volumes. In each reaction, 0, 0.1, 0.3, 1.0, 3.0, 10.0, 30.0
and 100.0 μM of RT inhibitors were added for ZDV-TP,
3TC-TP, TFV-DP and NVP while 0, 0.01, 0.03, 0.10,
0.30, 1.00,3.00 and 10.00 μM were added for EFV and
ETR. The reactions were incubated at 37°C for 30 min
and the reactions were terminated by adding 0.2 ml of
10% cold trichloracetic acid (TCA) and 20 mM sodium
pyrophosphate and incubated for at least 30 min on ice.
The precipitated products were filtered through a 96-
well MutiScreen HTS FC filter plate (Millipore) and
sequentially washed with 200 μl of 10% TCA and 150 μl
of 95% ethanol. The radioactivity of incorporated pro-
ducts was analyzed by liquid scintillation spectrometry
using a 1450 MicroBeta TriLux Microplate Scintillation
and Luminescence Counter (Perkin Elmer). The 50%
inhibitory concentration (IC50) of each RTI was deter-
mined by nonlinear regression analysis using GraphPad
Prism software. For determination of RT sensitivities to
ZDV-TP, 150 μM sodium pyrophosphate was included
in each reaction.
Phenotypic RT inhibitor susceptibility assays
Phenotypic analysis of RT inhibitor susceptibility was
performed with wild type HIV-1 subtype B and Subtype
C viruses in a cell-based in vitro assay. Briefly, cord
blood mononuclear cells were infected for 2 h with var-
ious viral isolates and plated in 96-well plates, at a den-
sity of 5 × 106 cells per well, in the presence of each RT
inhibitor. The drug concentration ranges for the inhibi-
tors tested were as follows: ZDV (6.4-400 nM), 3TC
(3.2-2000 nM), TFV (16-10000 nM), NVP (3.2-2000
nM), EFV (0.05-160 nM), ETR (0.05-160 nM). After 3
days in culture, the culture wells were refreshed with
media containing the corresponding drug dilutions.
After 7 days, the culture supernatants were collected
a n da n a l y z e df o rR Ta c t i v i ty to determine the dose
response curve. The EC50 (50% drug effective concentra-
tion) was calculated using GraphPad Prism software
[12].
Efficiency of (-) ssDNA synthesis primed by tRNA3
Lys
Using a cell-free system, the efficiencies of synthesis of
(-) ssDNA by HIV-1 subtype B and subtype C RT
enzymes were monitored using human natural tRNA3
Lys
(Bio S&T, Lachine, Quebec, Canada) and an HIV-1 PBS
RNA primer-template system [40]. The PBS RNA was
in vitro transcribed from BSSH II-linearized pHIV-PBS
DNA by using T7-Megashortscript kit (Ambion, Austin,
TX) as described [41]. Human tRNA3
Lys, purified by
HPLC from placenta, was labeled at its 5’-end with [g-
32P]-ATP using a KinaseMax kit (Ambion) according to
the manufacturer’s instructions and heat annealed to the
RNA template by incubation for 2 min at 95°C followed
by 10 min at 70°C and slowly cooling to room tempera-
ture as described [28], with the modification that a 30 μl
mixture was used that contained 50 mM Tris-HCl (pH
7.8), 50 mM NaCl, 50 nM tRNA3
Lys,5 0n M
32P-labeled
template PBS RNA and RT enzymes. Synthesis of (-)
ssDNA was initiated by the addition of 6 mM MgCl2
and dNTPs. Aliquots were removed at different time
points and the reactions were stopped by adding 4
volumes of formamide sample buffer (96% of forma-
mide, 0.05% each of bromophenol blue and xylene cya-
nol FF and 20 mM EDTA). The products were
separated on 6% polyacrylamide-7 M urea gels and were
exposed to x-ray film after gel drying. The intensity of
gel bands was analyzed with Scion Image software
(Scion Corp., Frederick, MD).
Processivity assays
The processivity of recombinant RT proteins was ana-
lysed using both homopolymeric and heteropolymeric
RNA templates in the presence of a heparin enzyme
trap to ensure a single processive cycle, i.e., a single
round of binding and of primer extension and dissocia-
tion. Assays on homopolymeric RNA were performed as
described elsewhere [29,43]. The primer-templates were
annealed by heating the solution of
32P-end-labeled
oligo dT12-18 (GE Healthcare) with an equimolar con-
centration of poly (rA) homopolymeric RNA template
(GE Healthcare) to 90°C for 2 min and incubating the
solution for an additional 10 min at 70°C, followed by
slow cooling to room temperature. RT enzymes and
T/Ps were preincubated for 5 min at 37°C in the same
buffer system as described above for (-)ssDNA synthesis.
Reactions were initiated by the addition of dTTP and
heparin trap (final concentration 2 mg/ml) and incu-
b a t e da t3 7 ° Cf o r1 0m i n ;2μl of reaction mixture were
removed and mixed with 8 μl of formamide sample
buffer (90% formamide, 10 mM EDTA, and 0.1% each
of xylene cyanol and bromophenol blue). Reaction
products were heat denatured and analyzed by 6% dena-
turing polyacrylamide gel electrophoresis and phosphor-
imaging. The effectiveness of the trap was assessed and
verified in pilot experiments in which the heparin trap
at various concentrations was preincubated with sub-
strates before the addition of RT enzymes.
In assays performed on heteropolymeric RNA, HIV
RNA template was prepared in vitro using the MEGA-
script™ transcription kit (Ambion, Austin, TX) from
ACC I-linearized plasmid pHIV-PBS DNA, which con-
sists of a 497-base pair HIV-1 sequence spanning the R
region of the HIV-1 long terminal repeat and a portion
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complementary to the 5’ end of the gag sequence. The
primers were [g-
32P]-ATP-labeled and filtered by Nuc-
Away spin column (Ambion, Austin, TX). The tem-
plate/primer complex was prepared as follows: the
template and primer were mixed at a molar ratio of 1:1,
denatured at 85°C for 5 min, and then sequentially
cooled to 55°C for 8 min and 37°C for 5 min to allow
for specific annealing of primer to the template. Reac-
tions were performed as above except that three differ-
ent concentrations of dNTPs were used.
Misincorporation assay
The template-primer ppt57D/ppt17D was used to deter-
mine the extent of misincorporation in the absence of
one complementary dNTP. The 17-mer DNA primer
ppt17D was
32P-labeled at the 5’end by [g-
32P]-ATP
using a KinaseMax Kit (Ambion) and annealed to the
57-mer DNA template at a molar ratio of 1:3. Reaction
mixtures (20 μl) contained 50 nM template/primer,
recombinant RT enzymes at equal activities, 50 mM
Tris·HCl, pH 7.8, 60 mM KCl, and 6 mM MgCl2.R e a c -
tions were incubated at 37°C for 5 min in the presence
of all four dNTPs (250 μM each) or in the presence of 3
dNTPs by excluding one complementary dNTP. Reac-
tions were stopped by adding 4 volumes of formamide
sample buffer (96% of formamide, 0.05% each of bromo-
phenol blue and xylene cyanol FF and 20 mM EDTA).
The products were denatured by heating at 90°C for
3 min, separated on 6% polyacrylamide-7 M urea gels,
and exposed to x-ray film after gel drying.
RT-catalyzed RNase H Activity
Intrinsic RNase H assays were performed as reported
[44]. RNase H activity was assayed on 40-mer 5’-end
32P-labeled heteropolymeric RNA template kim40R
annealed to the complementary 32-mer DNA oligomer
kim32D at a 1:4 molar ratio [45]. Reactions were con-
ducted at 37°C in mixtures containing 200 nM RNA-
DNA duplex substrate with equal RT activities in assay
buffer of 50 mM Tris-HCl, pH 7.8, 60 mM KCl, in the
presence or absence of heparin trap (2 mg/ml). Reac-
tions were initiated by adding 1/10 vol of 50 mM
MgCl2. Aliquots were removed at different times after
initiation of reactions and quenched by adding 4
volumes of formamide loading dye. The samples were
heated at 90°C for 3 min, cooled on ice, and electro-
phoresed through 6% polyacrylamide-7M urea gels. The
gels were analyzed by phosphorimaging. The efficacy of
the heparin trap was verified by pre-incubation experi-
ments performed by 10-min preincubation of various
concentrations of heparin trap with substrates in the
presence of magnesium followed by initiation of the
reaction with RT enzymes.
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